These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 12707229)

  • 1. Is iron gluconate really safer than iron dextran?
    Eichbaum Q; Foran S; Dzik S
    Blood; 2003 May; 101(9):3756-7. PubMed ID: 12707229
    [No Abstract]   [Full Text] [Related]  

  • 2. The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate.
    Fishbane S; Kowalski EA
    Semin Dial; 2000; 13(6):381-4. PubMed ID: 11130261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parenteral iron therapy options.
    Silverstein SB; Rodgers GM
    Am J Hematol; 2004 May; 76(1):74-8. PubMed ID: 15114602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans.
    Faich G; Strobos J
    Am J Kidney Dis; 1999 Mar; 33(3):464-70. PubMed ID: 10070910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of reaction to ferric gluconate in hemodialysis patients with a history of severe reaction to iron dextran.
    Bastani B; Rahman S; Gellens M
    ASAIO J; 2002; 48(4):404-6. PubMed ID: 12141472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypersensitivity reactions and deaths associated with intravenous iron preparations.
    Bailie GR; Clark JA; Lane CE; Lane PL
    Nephrol Dial Transplant; 2005 Jul; 20(7):1443-9. PubMed ID: 15855210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addressing patient concerns about intravenous iron therapy.
    Robbins KC
    Nephrol Nurs J; 2003 Apr; 30(2):220-4, 258. PubMed ID: 12737000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of available intravenous iron preparations in hemodialysis.
    Palmer K; Cameron K; Battistella M
    CANNT J; 2013; 23(2):51-4; quiz 55-6. PubMed ID: 24069699
    [No Abstract]   [Full Text] [Related]  

  • 9. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease.
    Auerbach M; Al Talib K
    Kidney Int; 2008 Mar; 73(5):528-30. PubMed ID: 18274543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium ferric gluconate complex in the treatment of iron deficiency for patients on dialysis.
    Fishbane S; Wagner J
    Am J Kidney Dis; 2001 May; 37(5):879-83. PubMed ID: 11325667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Parenteral iron replacement].
    Cynke E
    Praxis (Bern 1994); 1997 May; 86(20):835-6. PubMed ID: 9312810
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis.
    Pai AB; Boyd AV; McQuade CR; Harford A; Norenberg JP; Zager PG
    Pharmacotherapy; 2007 Mar; 27(3):343-50. PubMed ID: 17316146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical update: intravenous iron for anaemia.
    Auerbach M; Ballard H; Glaspy J
    Lancet; 2007 May; 369(9572):1502-1504. PubMed ID: 17482969
    [No Abstract]   [Full Text] [Related]  

  • 14. Is low-molecular weight iron dextran really the most risky iron?--Unconvincing data from an unconvincing study.
    DeLoughery TG; Auerbach M
    Am J Hematol; 2016 May; 91(5):451-2. PubMed ID: 26873795
    [No Abstract]   [Full Text] [Related]  

  • 15. Safe administration of iron sucrose in a patient with a previous hypersensitivity reaction to ferric gluconate.
    Sane R; Baribeault D; Rosenberg CL
    Pharmacotherapy; 2007 Apr; 27(4):613-5. PubMed ID: 17381390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the reported rates of hypersensitivity reactions associated with iron dextran and ferric carboxymaltose based on global data from VigiBase™ and IQVIA™ MIDAS® over a ten-year period from 2008 to 2017.
    Durup D; Schaffalitzky de Muckadell P; Strom CC
    Expert Rev Hematol; 2020 May; 13(5):557-564. PubMed ID: 32129113
    [No Abstract]   [Full Text] [Related]  

  • 17. Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients.
    Coyne DW; Adkinson NF; Nissenson AR; Fishbane S; Agarwal R; Eschbach JW; Michael B; Folkert V; Batlle D; Trout JR; Dahl N; Myirski P; Strobos J; Warnock DG;
    Kidney Int; 2003 Jan; 63(1):217-24. PubMed ID: 12472786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran.
    Michael B; Coyne DW; Fishbane S; Folkert V; Lynn R; Nissenson AR; Agarwal R; Eschbach JW; Fadem SZ; Trout JR; Strobos J; Warnock DG;
    Kidney Int; 2002 May; 61(5):1830-9. PubMed ID: 11967034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: Experience with a large dose (500 mg) of intravenous iron dextran and iron saccharate in peritoneal dialysis patients.
    Hörl WH
    Perit Dial Int; 2001; 21(5):527-8. PubMed ID: 11757843
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparative rates of adverse events with different formulations of intravenous iron.
    Okam MM; Mandell E; Hevelone N; Wentz R; Ross A; Abel GA
    Am J Hematol; 2012 Nov; 87(11):E123-4. PubMed ID: 22965928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.